1191272-70-4 Usage
Pyrrole ring
A five-membered aromatic ring with four carbon atoms and one nitrogen atom, contributing to the compound's stability and aromaticity.
Carboxylic acid group
A functional group (-COOH) that provides acidity and can form hydrogen bonds, which may influence the compound's solubility and reactivity.
Methyl ester
A functional group (-COOCH3) derived from the esterification of the carboxylic acid group, which can affect the compound's reactivity, volatility, and solubility.
Dimethylamino group
Two methyl groups (-CH3) attached to a nitrogen atom (-N(CH3)2), which can influence the compound's basicity, solubility, and steric hindrance.
Methylphenyl group
A phenyl ring (-C6H5) with a methyl substituent (-CH3), contributing to the compound's structure, stability, and potential applications in various fields.
Structural diversity
The presence of various functional groups and structural elements, which may lead to a wide range of potential applications in pharmaceuticals, agrochemicals, or materials science.
Potential applications
Due to its complex structure and functional groups, this chemical compound may have uses in pharmaceuticals, agrochemicals, or materials science, but further research is needed to determine its specific properties and uses.
Check Digit Verification of cas no
The CAS Registry Mumber 1191272-70-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,9,1,2,7 and 2 respectively; the second part has 2 digits, 7 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1191272-70:
(9*1)+(8*1)+(7*9)+(6*1)+(5*2)+(4*7)+(3*2)+(2*7)+(1*0)=144
144 % 10 = 4
So 1191272-70-4 is a valid CAS Registry Number.
1191272-70-4Relevant academic research and scientific papers
HETEROCYCLIC COMPOUNDS AS ERK INHIBITORS
-
Paragraph 0113; 0125; 0126, (2016/12/22)
Disclosed herein is a compound of formula (I) and/or a pharmaceutically acceptable salt thereof that can serve as Erk inhibitors. They are potentially useful in the treatment of diseases treatable by inhibition of Erk, such as cancers. Also disclosed herein is a pharmaceutical composition comprising a compound of formula (I) and/or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
HETEROCYCLIC COMPOUNDS FOR TREATING PSORIASIS
-
Paragraph 0128-0129, (2016/12/22)
Disclosed herein is a method of treating psoriasis involving the use of compound of formula I and/or a pharmaceutically acceptable salt thereof
Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control
Aronov, Alex M.,Qing, Tang,Martinez-Botella, Gabriel,Bemis, Guy W.,Cao, Jingrong,Chen, Guanjing,Ewing, Nigel P.,Ford, Pamella J.,Germann, Ursula A.,Green, Jeremy,Hale, Michael R.,Jacobs, Marc,Janetka, James W.,Maltais, Francois,Markland, William,Namchuk, Mark N.,Nanthakumar, Suganthini,Poondru, Srinivasu,Straub, Judy,Ter Haar, Ernst,Xiaoling, Xie
experimental part, p. 6362 - 6368 (2010/03/31)
The Ras/Raf/MEK/ERK signal transduction, an oncogenic pathway implicated in a variety of human cancers, is a key target in anticancer drug design. A novel series of pyrimidylpyrrole ERK inhibitors has been identified. Discovery of a conformational change
